Condition: Bladder Cancer · Bladder Cancer Recurrent · Neoplasm Recurrence · Sponsor: Verity Pharmaceuticals Inc.
The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.
This description comes directly from the study's public registry record.
Taniya Mann, PhD, MBA · 800-977-9778 · medinfo@veritypharma.com
Always discuss trial participation with your own doctor first.
| Site 05 | Vancouver, British Columbia, Canada | Recruiting |
| Site 04 | Kingston, Ontario, Canada | Recruiting |
| Site 01 | Toronto, Ontario, Canada | Recruiting |
| Site 02 | Toronto, Ontario, Canada | Not Yet Recruiting |
| Site 08 | Toronto, Ontario, Canada | Recruiting |
| Site 10 | Montreal, Quebec, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05037279